CBRE vs PACB · P/E 43, rev $35.77B vs rev $38.4M
CBRE Group Inc Class A (CBRE) versus Pacific Biosciences of California (PACB) — a side-by-side from cached financials, not a winner call.
CBRE Group Inc Class A (CBRE) is a real estate services company listed on US.
Pacific Biosciences of California (PACB) is a medical devices company listed on US.
Latest reported CBRE revenue for 2024-12-31 was $35.77B. Net income was $1.04B. Revenue was up 12.0% from 2023-12-31 to 2024-12-31. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
Latest reported PACB revenue for 2025-09-30 was $38.4M. Net income was -$38.0M. Revenue was down 3.3% from 2025-06-30 to 2025-09-30. PACB currently screens at market cap $387.1M.
CBRE currently screens at market cap $41.66B and trailing P/E 42.7. PACB currently screens at market cap $387.1M.
Not investment advice. Open the CBRE and PACB stock pages for the full models.
Not investment advice.